WallStreetZenWallStreetZen

NASDAQ: ADXN
Addex Therapeutics Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ADXN stock forecasts and price targets.

Forecast return on equity

Is ADXN forecast to generate an efficient return?

Company
N/A
Industry
68.88%
Market
359.96%

Forecast return on assets

Is ADXN forecast to generate an efficient return on assets?

Company
N/A
Industry
21.97%

ADXN earnings per share forecast

What is ADXN's earnings per share in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.04

ADXN revenue forecast

What is ADXN's revenue in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
$765.0k+286.03%
Avg 2 year Forecast
$0.0-100%
ADXN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ADXN revenue growth forecast

How is ADXN forecast to perform vs Biotechnology companies and vs the US market?

Company
286.03%
Industry
12,714.74%
Market
1,548.07%
ADXN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ADXN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ADXN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADXN$7.66N/AN/A
APVO$6.41N/AN/A
TOVX$0.18N/AN/A
APM$0.83N/AN/A
VIVS$2.35N/AN/A
View Top Biotech Stocks

Addex Therapeutics Stock Forecast FAQ

What is ADXN's earnings growth forecast for 2026-2026?

(NASDAQ: ADXN) Addex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 182.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,345.06%.

Addex Therapeutics's earnings in 2026 is -$7,621,243.

In 2026, ADXN is forecast to generate -$4,011,607 in earnings, with the lowest earnings forecast at -$3,854,289 and the highest earnings forecast at -$4,129,595.

If you're new to stock investing, here's how to buy Addex Therapeutics stock.

What is ADXN's revenue growth forecast for 2026-2027?

(NASDAQ: ADXN) Addex Therapeutics's forecast annual revenue growth rate of 286.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 12,714.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,548.07%.

Addex Therapeutics's revenue in 2026 is $198,172.On average, 4 Wall Street analysts forecast ADXN's revenue for 2026 to be $75,217,631, with the lowest ADXN revenue forecast at $0, and the highest ADXN revenue forecast at $154,859,828.

In 2027, ADXN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ADXN's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: ADXN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 21.97%.

What is ADXN's Earnings Per Share (EPS) forecast for 2026-2026?

(NASDAQ: ADXN) Addex Therapeutics's current Earnings Per Share (EPS) is -$0.06. In 2026, ADXN's EPS is forecast to hit -$0.04 (min: -$0.04, max: -$0.04).

What is ADXN's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: ADXN) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.